Intradermal immunization with outer membrane protein 25 protects Balb/c mice from virulent B. abortus 544

Goel, Divya; Bhatnagar, Rakesh

doi:10.1016/j.molimm.2012.02.126

Cited by 53 publications

(44 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[17–20]. Several Brucella proteins have been used as immunogens for experimental subunit vaccine formulations, including outer membrane proteins, namely Omp16, Omp19, Omp31, Omp28, and Omp25 [21–24], ribosomal protein L7/L12 [17,25], Cu-Zn superoxide dismutase [26], a cytoplasmic protein p39 [27], lumazine synthase BLS [28], among others. In addition, experimental DNA vaccines [28,29] as well as vectored vaccines using deliver vectors such as Salmonella enterica serotype Typhimurium [30], Escherichia coli [31], Yersinia enterocolitica [32], Lactococcus lactis [33], and the influenza virus [34] have been increasingly studied.…”

Section: Introductionmentioning

confidence: 99%

Meta-Analysis and Advancement of Brucellosis Vaccinology

et al. 2016

View full text Add to dashboard Cite

Background/ObjectivesIn spite of all the research effort for developing new vaccines against brucellosis, it remains unclear whether these new vaccine technologies will in fact become widely used. The goal of this study was to perform a meta-analysis to identify parameters that influence vaccine efficacy as well as a descriptive analysis on how the field of Brucella vaccinology is advancing concerning type of vaccine, improvement of protection on animal models over time, and factors that may affect protection in the mouse model.MethodsA total of 117 publications that met the criteria were selected for inclusion in this study, with a total of 782 individual experiments analyzed.ResultsAttenuated (n = 221), inactivated (n = 66) and mutant (n = 102) vaccines provided median protection index above 2, whereas subunit (n = 287), DNA (n = 68), and vectored (n = 38) vaccines provided protection indexes lower than 2. When all categories of experimental vaccines are analyzed together, the trend line clearly demonstrates that there was no improvement of the protection indexes over the past 30 years, with a low negative and non significant linear coefficient. A meta-regression model was developed including all vaccine categories (attenuated, DNA, inactivated, mutant, subunit, and vectored) considering the protection index as a dependent variable and the other parameters (mouse strain, route of vaccination, number of vaccinations, use of adjuvant, challenge Brucella species) as independent variables. Some of these variables influenced the expected protection index of experimental vaccines against Brucella spp. in the mouse model.ConclusionIn spite of the large number of publication over the past 30 years, our results indicate that there is not clear trend to improve the protective potential of these experimental vaccines.

show abstract

Section: Introductionmentioning

confidence: 99%

Meta-Analysis and Advancement of Brucellosis Vaccinology

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Some studies have reported that Th1/Th2 balance is disturbed in response to stress or infection by antigens, resulting in the shift toward Th2-dominant immunity (38,39). Furthermore, the levels of IgG1 and IgG2a were shown to increase after immunization with the recombinant outer membrane protein 25 in mice, although no significant increase in cytokine-secreting splenocyte population was observed (40).…”

Section: Discussionmentioning

confidence: 97%

Comparative Analysis of Immune Responses to Outer Membrane Antigens OMP10, OMP19, and OMP28 of <i>Brucella abortus</i>

Park

Jung

et al. 2018

Jpn J Infect Dis

View full text Add to dashboard Cite

SUMMARY:Brucella infection is accompanied by cytokine production, which serves as an important factor to evaluate the innate and adaptive immune responses. Several researchers have been investigating the mechanisms involved in Brucella infection in the host. Here, we conducted an analytical study to define pathogenic pathways and immune mechanisms involved in Brucella infection by investigating the antigenic efficacy of recombinant outer membrane protein 10 (rOMP10), outer membrane protein 19 (rOMP19), and outer membrane protein 28 (rOMP28) in vitro and in vivo upon stimulation/immunization. Cytokine production was analyzed by nitric oxide (NO) assay and enzyme-linked immunosorbent assay (ELISA) after stimulation of RAW 264.7 cells and naive splenocytes with the recombinant proteins. Our results show that levels of NO, tumor necrosis factor (TNF)-α, and interleukin (IL)-6 increased in RAW 264.7 cells in a time-dependent manner following recombinant protein stimulation. In contrast, levels of interferon (IFN)-γ and IL-2 increased in naive splenocytes after stimulation with proteins. ELISA and ELISpot assays were performed after immunization of mice with recombinant proteins. rOMP28 greatly increased IFN-γ, IL-2, and TNF-α levels than IL-4 and IL-6 levels in vitro. Of the recombinant proteins, rOMP19 elicited a mixed Th1/Th2 immune response by increasing the number of IgG-secreting cells in vivo.

show abstract

“…With the aid of published reports, the candidate ORFs were further selected if they were co-regulated with known Brucella virulence factors or had direct evidence for a role in pathogenesis. The use of pathogenesis-associated bacterial factors as antigens in vaccine preparations have been shown to confer protective immunity against Brucella and other important intracellular pathogens [24], [25], [26], [27]. This resulted in 9 candidate ORFs.…”

Section: Methodsmentioning

confidence: 99%

Immunogenic and Invasive Properties of Brucella melitensis 16M Outer Membrane Protein Vaccine Candidates Identified via a Reverse Vaccinology Approach

et al. 2013

View full text Add to dashboard Cite

Brucella is the etiologic agent of brucellosis, one of the most common and widely distributed zoonotic diseases. Its highly infectious nature, the insidious, systemic, chronic, debilitating aspects of the disease and the lack of an approved vaccine for human use in the United States are features that make Brucella a viable threat to public health. One of the main impediments to vaccine development is identification of suitable antigens. In order to identify antigens that could potentially be used in a vaccine formulation, we describe a multi-step antigen selection approach. We initially used an algorithm (Vaxign) to predict ORF encoding outer membrane proteins with antigenic determinants. Differential gene expression during acute infection and published evidence for a role in virulence were used as criteria for down-selection of the candidate antigens that resulted from in silico prediction. This approach resulted in the identification of nine Brucella melitensis outer membrane proteins, 5 of which were recombinantly expressed and used for validation. Omp22 and Hia had the highest in silico scores for adhesin probability and also conferred invasive capacity to E. coli overexpressing recombinant proteins. With the exception of FlgK in the goat, all proteins reacted to pooled sera from exposed goats, mice, and humans. BtuB, Hia and FlgK stimulated a mixed Th1–Th2 response in splenocytes from immunized mice while BtuB and Hia elicited NO release from splenocytes of S19 immunized mice. The results support the applicability of the current approach to the identification of antigens with immunogenic and invasive properties. Studies to assess immunogenicity and protective efficacy of individual proteins in the mouse are currently underway.

show abstract

Intradermal immunization with outer membrane protein 25 protects Balb/c mice from virulent B. abortus 544

Cited by 53 publications

References 36 publications

Meta-Analysis and Advancement of Brucellosis Vaccinology

Meta-Analysis and Advancement of Brucellosis Vaccinology

Comparative Analysis of Immune Responses to Outer Membrane Antigens OMP10, OMP19, and OMP28 of <i>Brucella abortus</i>

Immunogenic and Invasive Properties of Brucella melitensis 16M Outer Membrane Protein Vaccine Candidates Identified via a Reverse Vaccinology Approach

Contact Info

Product

Resources

About